Recently, a novel corona virus (COVID-19), identified as one of the acute respiratory syndrome corona virus (SARS CoV-2) and emerged as a pandemic disease in Asia and European countries in 2020. The World Health Organization (WHO) has declared the current outbreak as a global public health crisis. Due to the variability in the amino acid and amino acid sequences, it does not develop suitable vaccines against the viral proteins. Hence, the inhibitor to be developed against the viral proteins of the corona virus is a promising idea to develop structure-based drugs from the photochemical compounds. Here, the novel drug was identified and well studied against the viral receptors by using the molecular docking technique. Phytocompound 6-gingerol possesses excellent drug likeliness with zero violations and very good pharmacokinetic properties with the highest binding affinity ranging from -2.8764 KJ/mol to -15.7591 KJ/mol with various COVID-19 viral protein targets. Our study reveals that 6-gingerol from ginger could act as a promising drug of choice to treat COVID-19.
